|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
|
|
|
|||||||||
|
|||||||||||
|
J Am Coll Cardiol, 1990; 16:424-429 © 1990 by the American College of Cardiology Foundation |
Department of Cardiology, Medical School, University of Padua, Italy.
Vasodilating agents acutely reduce regurgitant volume and improve left ventricular performance in aortic regurgitation, but more information is necessary about their long-term efficacy. To evaluate the effects of 12 months of therapy with nifedipine, a randomized, double-blind, placebo-controlled trial was performed in 72 asymptomatic patients with severe aortic regurgitation. At 12 months, patients receiving nifedipine had a significant reduction in left ventricular end-diastolic volume index (110 +/- 19 versus 136 +/- 22 ml/m2, p less than 0.01) and mass (115 +/- 19 versus 142 +/- 16 g/m2, p less than 0.01) measured by two-dimensional echocardiography. They also had a reduction in left ventricular mean wall stress (360 +/- 27 versus 479 +/- 36 kdyne/cm2, p less than 0.001) and an increase in ejection fraction (72 +/- 8% versus 60 +/- 6%, p less than 0.05). These data show that the long-term unloading action of nifedipine is able to reverse left ventricular dilation and hypertrophy and suggest that such therapy has the potential to delay the need for valve replacement in asymptomatic patients.
This article has been cited by other articles:
|
|
 |
|
  R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): e1 - e148. [Full Text] [PDF]
|
|
|
|
|
|
R. O. Bonow, B. A. Carabello, K. Chatterjee, A. C. de Leon Jr, D. P. Faxon, M. D. Freed, W. H. Gaasch, B. W. Lytle, R. A. Nishimura, P. T. O'Gara, et al. ACC/AHA 2006 Practice Guidelines for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) Developed in Collaboration With the Society of Cardiovascular Anesthesiologists Endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons J. Am. Coll. Cardiol., August 1, 2006; 48(3): 598 - 675. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Evangelista, P. Tornos, A. Sambola, G. Permanyer-Miralda, and J. Soler-Soler Long-term vasodilator therapy in patients with severe aortic regurgitation. N. Engl. J. Med., September 29, 2005; 353(13): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. A. Carabello Vasodilators in aortic regurgitation--where is the evidence of their effectiveness? N. Engl. J. Med., September 29, 2005; 353(13): 1400 - 1402. [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bekeredjian and P. A. Grayburn Valvular Heart Disease: Aortic Regurgitation Circulation, July 5, 2005; 112(1): 125 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Enriquez-Sarano and A. J. Tajik Aortic Regurgitation N. Engl. J. Med., October 7, 2004; 351(15): 1539 - 1546. [Full Text] [PDF]
|
|
|
|
 |
|
 Y J Kim, M Jones, T Shiota, H Tsujino, J X Qin, F Bauer, M Sitges, J Kwan, L A Cardon, A D Zetts, et al. Effect of load alterations on the effective regurgitant orifice area in chronic aortic regurgitation Heart, October 1, 2002; 88(4): 397 - 400. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N A Boon and P Bloomfield The medical management of valvar heart disease Heart, April 1, 2002; 87(4): 395 - 400. [Full Text] [PDF]
|
|
|
|
|
|
Y. Mori, M. Nakazawa, H. Tomimatsu, and K. Momma Long-term effect of angiotensin-converting enzyme inhibitor in volume overloaded heart during growth: a controlled pilot study J. Am. Coll. Cardiol., July 1, 2000; 36(1): 270 - 275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Manyari, A. Yunus, L. J. Klein, C. L.A. Reichert, A. E.R. Arnold, A. J.S. Coats, R. Scognamiglio, and S. H. Rahimtoola Nifedipine in Severe Aortic Regurgitation N. Engl. J. Med., May 11, 1995; 332(19): 1302 - 1304. [Full Text]
|
|
|
|
|
|
R. Scognamiglio, S. H. Rahimtoola, G. Fasoli, S. Nistri, and S. D. Volta Nifedipine in Asymptomatic Patients with Severe Aortic Regurgitation and Normal Left Ventricular Function N. Engl. J. Med., September 15, 1994; 331(11): 689 - 694. [Abstract] [Full Text]
|
|
|
|
|
|
R. O. Bonow Management of Chronic Aortic Regurgitation N. Engl. J. Med., September 15, 1994; 331(11): 736 - 737. [Full Text]
|
|
|
|
 |
|
 NIFEDIPINE MAY PROTECT LEFT VENTRICLE IN AORTIC REGURGITATION Journal Watch (General), August 14, 1990; 1990(814): 2 - 2. [Full Text]
|
|
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |
